Clinical trial · Interventional
Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)
NCT02118415CI-TRIAL-00076158completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC Stage IIIA/B | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hsp70-peptide TKD/IL-2 activated, autologous NK cells | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Interventional
- description
- Interventional group: activated autologous NK cells as a drug
- interventionNames
- Other: Hsp70-peptide TKD/IL-2 activated, autologous NK cells
- type
- NO_INTERVENTION
- label
- Control group
- description
- Control group: BSC
Primary outcomes (1)
- measure
- Progress free survival
- timeFrame
- follow up after randomization for at least 18 months
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * First diagnosis of histologically and/or cytologically proven and unresectable NSCLC with clinically stage III A and III B * Completion of radiochemotherapy no longer than 8 weeks ago * Progression free according to RECIST criteria at the first assessment after completion of RCTx * Confirmed presence of Hsp70 on patient´s tumors * ECOG Status(Appendices) ≤ 2 Exclusion Criteria: * Any severe heart disease or any severe concomitant disease (ECOG stage \> 2) * NSCLC patients (stage IIIA/B) eligible for initial surgery with a confirmed consent of an interdisciplinary tumorboard * Patients that show ALK positivity or an activating mutation of the EGFR-TK domain * Patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology * Receipt of immunosuppressive drugs including high dose systemic corticosteroids within 3 weeks before study entry. Low dose corticosteroids as they are a common treatment option for patients suffering from COPD are not an exclusion criterium
References
Publications (0)
Data not yet available
No reference posted for this study.